ClinicaliQ Trial Snapshot
- A Study of TAK-755 in Adults With Acute Ischemic Stroke — Recruiting • Phase II • Cardiology / Cardiovascular • NCT07392450.
- What is being tested: TAK-755, an investigational therapeutic agent, is being evaluated for safety and efficacy in treating acute ischemic stroke caused by blood clots (thrombotic or embolic occlusion) in adults.
- Patient eligibility overview: The trial enrolls adult patients presenting with acute ischemic stroke requiring urgent intervention, with specific inclusion criteria based on stroke severity, timing from symptom onset, and clinical presentation criteria determined by the research protocol.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Acute ischemic stroke (AIS) is a medical emergency that happens because of a sudden stop of blood flow to a part of the brain. This happens when a blood clot forms within the vessel (known as thrombotic occlusion) or a clot originating from somewhere else blocks a blood vessel (known as embolic occlusion). Strokes can cause serious health problems, death, and affect one's quality of life. To reduce long-term damage, it is important to restore blood flow to the brain as soon as possible. The main aim of this study…
Eligibility Snapshot
- : Informed Consent: 1. The participant or legally authorized representative has provided informed consent or deferred consent eligibility confirmed before the initiation of any trial procedures. Age: 2. greater than and equal to (>=) 18 years of age, inclusive, at the time of signing the Informed Consent Form (ICF) or confirmation of deferred consent eligibility. Clinical Characteristics: 3. Clinical diagnosis of AIS. 4. Onset of stroke symptoms within 24 hours of randomization. Wake-up strokes may be included if Last Known Well is within 24 hours of randomization; time of onset will be considered the time of Last Known Well. 5. National Institutes of Health Stroke Scale score of 5 to 25, indicating moderate to severe stroke. Participants with an NIHSS score of 5 are eligible only if at least 1 predefined disabling neurological deficit is present, as defined by one or more of the following NIHSS criteria: * Complete hemianopia (NIHSS visual score >=2). * Aphasia impairing meaningful communication (NIHSS language score >=2). * Motor deficit with inability to sustain effort against gravity (NIHSS left or right motor arm or leg score >=2). 6. Estimated Modified Rankin Scale score less than (130 kilograms (kg) or
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.